Articles related to COLORECTAL CANCER (CRC)

A total of 246 patients were randomly allocated to one of two groups: adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer (combination group) or FTD-TPI alone (FTD-TPI group). The median overall survival in the combo group was 10.8 months and 7.5 months in the FTD-TPI group. The median progression-free survival in the combo group was 5.6 months and 2.4 months in the FTD-TPI group.

When body mass index (BMI) at the time of recruitment was taken into account in this case-control study, an inverse correlation between being overweight and the risk of CRC was found. However, when looking at BMI at earlier times, a clear positive association between BMI and CRC risk emerged, which was especially pronounced for BMI eight or more years ago. Recent weight loss was also strongly associated with increased CRC risk.

According to the findings of this study, patients with rectal cancer who were monitored using a watch-and-wait approach had a good quality of life, with some patients reporting bowel and sexual dysfunction. When patients needed surgery, their quality of life and functional outcome deteriorated. These findings will be useful in daily practice to advise patients on what to expect from a wait-and-see approach.

A 56-year-old man with no significant medical history, who previously refused colonoscopy for colorectal cancer screening, visited his primary care physician. Despite the physician’s recommendations, the patient declined colonoscopy and instead preferred a less invasive screening test. The patient had no symptoms of colorectal issues but had a family history of his father dying from colorectal cancer at age 80. The patient’s hemoglobin level was within the normal range at 13.7 g/dL.

Immunotherapy combinations with activity in patients with microsatellite stable (MSS) metastatic colorectal cancer are needed, and the recommended phase 2 dose of RIN had a manageable safety profile and an overall response rate of 27.6%, a median progression-free survival of 4 months, and a median overall survival of 20 months in this nonrandomized clinical trial of 39 patients with metastatic colorectal cancer. Patients with no liver metastases received responses (overall response rate, 36.4%; median overall survival not reached).

Medical oncologists, pathologists, gastroenterologists, and other oncology HCPs who participate in this CME activity should be better able to determine appropriate testing to personalize treatment for HER2+ metastatic colorectal cancer patients (mCRC) and summarize clinical data from existing and emerging treatment options for HER2+ mCRC patients.